Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Somebody bought a bunch of shares... and now it's being
taken right back down 1 or 2 cents at a time in hundred share lots!!
I still really like this stock and am hoping the merger closes before the end of the year.
Inventergy Comments on Current Environment for Intellectual Property
Download PDF
Company Sees a Positive Shift in the Industry
CAMPBELL, CA -- (Marketwired) -- 12/18/15 -- Inventergy Global, Inc. (NASDAQ: INVT) ("Inventergy" or the "Company") today provided an update to investors regarding its views on the prevailing intellectual property environment.
Joe Beyers, Chairman and CEO of Inventergy, said, "I recently attended the IP Dealmakers Forum in New York City (www.ipdealmakersforum.com), which brought together key participants across the field of intellectual property transactions and monetization. Notable participants commented that they believe the IP marketplace appears to be rebounding and expressed optimism about the importance and value of IP transactions, also noting that Congress is entering its holiday recess without having passed any new patent litigation reform legislation, currently under consideration and facing considerable debate. This additional delay enables further discussion by all critical stakeholders, helping to ensure that future changes, if any, are well thought out and the full consequences thoroughly understood and properly balanced, given the critical importance of a robust U.S. patent system to protect our innovation economy."
Another indication of the changes in the IP environment, as recently reported by RPX Corporation (www.rpxcorp.com, which among other things, provides patent market intelligence), is that filing rates of new inter partes review (IPR) of patent challenge cases at the United States Patent and Trademark Office (USPTO) have flattened over the last several years, and the success rates of such challenges have fallen. Denial rates at the petition stage by the USPTO have recently increased to 42% for complete denial of patent challenges and 16% granted review on only some of the challenged patent claims. And even for those cases where review is granted, only 57% (through September 2015) of such contested cases taken through full review resulted in all challenged claims being cancelled. Indeed, the survival rate of patent claims taken through the IPR challenge process appears to have nearly doubled over the past several years.
Mr. Beyers continued, "The view that filing IPRs against patents is a 'slam dunk' approach that companies can easily use to avoid reasonable licensing negotiations is being appropriately adjusted. The USPTO appears, in both process and outcomes, to be approaching more sensible and fair results.
"In summary, the IP industry seems to be at an inflection point. I believe that in 2016 and 2017 we will see the industry, lawmakers and the courts taking a more appropriate and balanced view of the value of IP and particularly patent rights in the United States," concluded Mr. Beyers.
Thanks for the comparison. It's enough to
convince me to fill out my position.
Shouldn't be long before the fireworks begin.
A settlement with Google sounds like what we've been waiting for. But I don't understand what kind of an announcement would be permitted. Is Mara allowed to say anything at this point?
Stocking of the MF? Let's see they consider it significant enough to announce before the next quarterly report.
What is "pp"
Were you told this recently?
Earnings call site, please
Arch Therapeutics Receives Notice of Allowance for New Patent in the United States
Patent Broadens Self-Assembling Peptide Technology Portfolio
FRAMINGHAM, MA -- (Marketwired) -- 12/03/15 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that the U.S. Patent Office has allowed a broad patent on the use of its self-assembling technology to prevent the formation of adhesions.
Arch has filed patent applications and has worldwide exclusive rights to intellectual property assigned jointly to the Massachusetts Institute of Technology (MIT) and Versitech Limited, the technology transfer company of the University of Hong Kong. The applications and rights cover self-assembling compositions and methods of making and using such compositions for medical applications including preventing bleeding; preventing the movement of bodily fluids, contaminants, etc., within or on the human body; preventing adhesions; treatment of leaky or damaged tight junctions; and reinforcement of weak or damaged vessels, such as aneurysms, with patents covering this technology in the United States, Europe, Japan, Canada, Australia, Hong Kong and China. Additional patent applications are pending in multiple jurisdictions.
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.
Natcore Technology closes first tranche of private placement
Rochester, NY — (December 1, 2015) — Natcore Technology Inc. (TSX-V: NXT; OTCQB: NTCXF) has completed the first tranche of its proposed non-brokered private placement, as announced on November 26, 2015. Gross proceeds of $610,000.00 were raised through the sale of 1,694,444 units at a price of $0.36 per unit. Each unit comprised one common share and one share purchase warrant. Each warrant entitles the holder to purchase of a further common share at $0.55 for a period of three years.
All securities issued in the initial tranche are subject to a hold period in Canada expiring on March 31, 2016. Proceeds of the placement will be applied to further development of Natcore’s technologies and general working capital.
Graphene 3D Lab Announces R&D-Royalty Agreement with a Fortune 500 Manufacturer
Dec 1, 2015 TSX-V: GGG, OTCQB: GPHBF
Graphene 3D Lab Announces R&D-Royalty Agreement
with a Fortune 500 Manufacturer
December 1, 2015 -- New York, NY -- Graphene 3D Lab Inc. (TSX-V: GGG, OTCQB: GPHBF) ("Graphene 3D") and Graphene Laboratories Inc. are pleased to announce they have signed a research, development and royalty agreement ("Agreement") with a Fortune 500 listed manufacturer. Initially, the Agreement encompasses the development of multi-phased deliverables over the course of the next 12 months. For competitive reasons and pursuant to confidentially clauses contained with the Agreement, neither specific research objectives nor the identity of the Agreement partner can be publically disclosed. Upon successful completion of the research phase, and subject to approval by the U.S. Food & Drug Administration, the developed materials will become a part of a consumer retail product.
The Agreement calls for all research and development costs and royalty obligations to be paid by the partner, as well as a first-right-of-refusal for supply of any graphene related materials in future manufacturing pertaining to Intellectual Property (IP) developed under the agreement. All IP developed under the scope of the Agreement will be jointly held by both parties. The partner has consecutively been included in the Fortune 500 list for over 15 years.
"Graphene is a complex and amazingly functional material with properties that provide unique advantages in a wide variety of manufacturing situations. We expect graphene to become a common ingredient in large-scale manufacturing, and the agreement announced today will likely be a common first-step for traditional manufactures," said Elena Polyakova Co-CEO of Graphene 3D. "Manufacturers want the benefits of graphene, but it is a highly-specialized material. We are helping partners develop solutions and processes to incorporate graphene into their existing manufacture processes."
"Our lab team will assist our partner to understand, handle and integrate graphene into future manufacturing," added Daniel Stolyarov, Co-CEO of Graphene 3D. "We are not just replacing other additives with graphene, we are working jointly with our partners to elevate the potential of their products. Product expertise from our partners, graphene expertise from our lab - the results is new products that can do more than before."
Research and development work will be completed by personnel from both Graphene 3D and Graphene Lab. Graphene 3D is in the late stages of acquiring Graphene Lab in an all-share, non-arms length transaction expected to close prior to the end of 2016, subject to approval from the TSX-V (See New Release dated: August 12, 2015). "Bringing Graphene Lab into Graphene 3D creates value for our existing shareholders by expanding the scope of commercial applications Graphene 3D can provide." stated Stolyarov. "Combining these two entities give us much broader expertise to support existing manufactures."
This news release is intended to fulfill all compliance, regulatory and TSX-V Exchange obligations relating to the disclosure of material news.
About Graphene 3D
Graphene 3D Lab is in the business of developing, manufacturing, and marketing proprietary graphene-based nanocomposite materials for various types of 3D printing, including fused filament fabrication. The Company is also involved in the design, manufacture, and marketing of 3D printers and related products for domestic and international customers.
The Graphene 3D Lab facility is located in Calverton, NY and is equipped with material processing and analytical equipment. The company has four US patent applications pending for its technology. For more information on Graphene 3D Lab, Inc., visit www.graphene3dlab.com.
About Graphene Laboratories
Graphene Laboratories Inc. ("GLI") is incorporated under the laws of the Commonwealth of Massachusetts, and is controlled and managed by Daniel Stolyarov and Elena Polyakova, insiders of Graphene 3D. GLI., a leader in manufacturing and retailing of graphene and advanced materials owns the Graphene Supermarket(r), www.graphene-supermarket.com, a leading supplier of such products to customers around the globe. Graphene Laboratories client list is comprised of more than 8,000 customers worldwide, including nearly every Fortune 500 tech company and major research university. Some notable clients are: NASA, Ford Motor Co., GE, Apple, Xerox, Samsung, Harvard University, IBM and Stanford University. For the last fiscal year ending December, 2014, GLI recorded annual revenues of in excess of USD $1,000,000 and was cash flow positive. Moreover, GLI has no material debt, and only trade creditors.
According to prior announcement dated August 12, 2015, the Graphene 3D has entered in non-arm length share exchange agreement (the "SEA") to acquire all issued and outstanding shares of Graphene Laboratories. The terms of the Share Exchange are subject to confirmation by a fairness opinion prepared by an independent business valuator, an audit of GLI's financial statements, the approval of the independent directors of the Company, and the acceptance for filing by the TSX Venture Exchange. Prior completion of the transaction, the financial record of GLI does not appear in published filing statements of Graphene 3D.
For further details concerning the Transaction, please see the Company's filing statement on SEDAR (www.sedar.com) under the Company's profile.
Except for statements of historical fact, all statements in this press release, including, but not limited to, statements regarding future plans, objectives and payments are forward-looking statements that involve various risks and uncertainties.
For more information, please contact:
Commercial Inquiries:
Daniel Stolyarov
Co-Chief Executive Officer
Telephone: (631) 405-5116
Email: daniel.stolyarov@graphene3dlab.com
Having listened to today's call I'm mildly encouraged. It seems to me that recently the whole focus of the company has become getting Zhongshan up and going while preparing to spin off what will become the most valuable part of this whole venture.
This has taken a bit more time than expected... but now we're very close.
Once it is started Ostrowski's pitch told me that revenues would flow much sooner than I expected, since they have an ever increasing amount of product to sell every few weeks; i.e. each time product moves from tank to tank.
Maybe, just maybe, we're finally at the bottom of this stock price decline.
Natcore Appoints Interim Chief Financial Officer
Rochester, NY — (November 27, 2015) —The Board of Directors of Natcore Technology Inc. (TSX-V: NXT; OTCQB: NTCXF) has accepted the resignation of John Meekison as Chief Financial Officer. Mr. Meekison has resigned due to other commitments.
The Board has appointed Richard Childs, CPA, CFE to be interim CFO.
Mr. Childs has a forensic accounting practice that serves more than 100 lawyers across the United States. He is a member of the American Institute of Certified Public Accountants and the Society of Certified Fraud Examiners, as well as a member of the New Jersey State Society of CPAs. In the private sector, he served for six years as Vice President, Director of Finance and Internal Security for Deak-Perera, the foreign exchange, Swiss banking and precious metals company. In the government sector, he has served as a fraud investigator for the Office of the (NJ) Attorney General; the Supervising Accountant for the Essex County (NJ) Division of Accounts and Control; and, most recently, as the Chief of the Union County (NJ) Sheriff’s Department Economic Crime/Inspection Bureau. Mr. Childs holds a Bachelor of Science degree in accounting from Rutgers University.
Mr. Meekison will retain his position on the Natcore Board of Directors.
Natcore Technology announces private placement.
Rochester, NY — (November 26, 2015) — Natcore Technology Inc. (TSX-V: NXT; OTCQB: NTCXF) is pleased to announce it intends to raise up to CND$3,000,000 via a non-brokered private placement.
The non-brokered private placement involves the sale of up to 8,333,333 units at a price of CND$0.36 per Unit for aggregate gross proceeds of CND$3,000,000. Each unit comprises one common share and one share purchase warrant. Each warrant will entitle the holder to purchase of a further common share at CND$0.55 for a period of three years from closing.
Finder’s fees may be payable on all or portion of the financing. Proceeds of the placement will be applied to further development of Natcore’s technologies and general working capital. The completion of the placement is subject to regulatory approval, including the approval of the TSX Venture Exchange.
Carog, I'm a multiyear shareholder who follows this board closely but doesn't post often. Many thanks for sharing your insights.
Is there any chance you've discussed the multiweek delays between posting results and the teleconferences used to discuss these results? If so could it be that the delays are intentional so that management might expect to be able to discuss pending announcements?
Given the 3q results and the teleconference that followed I'd now expect to see a surge of short covering.
Following with tears in my eyes.
Received the same paragraphs in a response from Natcore a couple of weeks ago...
Missing from my response was the phrase "If not, certainly early in the 1Q16."
Patience, patience, patience!!!
Oops... you're correct.
Now we have the complete elimination of silver
and still not a single sale!!
Natcore Video from New Orleans
Why up?
My guess.. serious buying.. possibly prearranged, by someone with the skill to realize a reasonably large position without substantially moving the stock price.
Maybe timed to coincide with selling by current shareholders who have given up on the an Oslo listing in the near future.
If Natcore is really coming to fruition the time should be near. Maybe you've found a yet undisclosed part of the master plan.
What is this Notice of Effectiveness (effect)???
Notice of Effectiveness (effect)
Print
Alert
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
NOTICE OF EFFECTIVENESS
Effective Date: October 06, 2015
Form: F-1
CIK: 0001464623
Company Name: Natcore Technology Inc.
File Number: 333-206666
Natcore Technology . (PC) (USOTC:NTCXF)
Historical Stock Chart
1 Year : From Oct 2014 to Oct 2015
Click Here for more Natcore Technology . (PC) Charts.
Natcore Technology . (PC) (USOTC:NTCXF)
Intraday Stock Chart
Today : Wednesday 7 October 2015
Click Here for more Natcore Technology . (PC) Charts.
Maybe, just maybe we'll be off and running again.
The Company expects to account for the transaction as revenue in its third quarter financial results to be announced approximately mid-November.
Looking forward to the long awaited announcement of a revenue stream. But what I fear is announcement of any more technology progress until it is ready to ship.
We need sales... not dangling carrots.
MediWound Awarded BARDA Contract Valued Up to $112 Million for Development and Procurement of NexoBrid for the U.S.
Contract Highlights Product's Merit and Therapeutic Impact, as well as Potential Role in Mass Casualty Preparedness
YAVNE, Israel, Sept. 30, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has awarded the Company a contract valued at up to $112 million. The contract is for the advancement of the development and manufacturing, as well as the procurement of NexoBrid®, the Company's proprietary pharmaceutical product for enzymatic removal of eschar in adults with deep-partial and full-thickness thermal burns, as a medical countermeasure as part of BARDA preparedness for mass casualty events.
The five-year base contract includes $24 million of funding to support development activities to complete the U.S. Food and Drug Administration (FDA) approval process for NexoBrid for use in thermal burn injuries, as well as $16 million for procurement of NexoBrid, which is contingent upon FDA Emergency Use Authorization (EUA) and/or FDA marketing authorization for NexoBrid. In addition, the contract includes options for further funding of up to $22 million for expanding NexoBrid's indications and of up to $50 million for additional procurement of NexoBrid.
"BARDA's commitment underscores the important role NexoBrid might play in preparing for mass casualty events where subsequent surgical capacity is limited and rapid severity assessment and intervention are imperative," stated Gal Cohen, President and Chief Executive Officer of MediWound. "This non-dilutive funding provides important recognition of the potential merits of NexoBrid and the therapeutic impact of our technology, as well as provides significant support for our ongoing clinical development and manufacturing programs. This contract frees up a portion of the Company's proceeds raised during the IPO, which were initially intended for use in clinical development of NexoBrid and now can be used to further advance our pipeline. We are very happy to join forces with the U.S. government in support of its preparedness programs for mass casualty events. We look forward to working with BARDA to have NexoBrid available for burn patients in the U.S."
The challenges of providing definitive burn care are heightened when delivering treatment after a mass casualty event in a resource-strained environment. The Government Accountability Office reports that in a mass casualty event, more than 10,000 patients might require thermal burn care, which will create bottlenecks in the ability to provide quality treatment and care for victims. Effective and rapid non-surgical debridement would increase treatment capacity to provide definitive wound healing to burn injuries. The use of non-surgical means that are capable of providing fast debridement without harming healthy tissues, particularly during public health emergencies, could potentially reduce the time, labor and resource burdens associated with the current standard-of-care, thereby enabling the treatment of more patients.
NexoBrid represents a new paradigm in burn care management having demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove in a single, four-hour application the dead or the damaged tissue (eschar) earlier than other modalities, without harming viable tissue. In clinical studies NexoBrid has demonstrated a significant reduction in surgical burden with long-term outcomes that are comparable to the current surgical treatment. NexoBrid was granted marketing authorization from the European Medicines Agency and the Israeli Ministry of Health for the removal of eschar in adults with deep partial and full-thickness thermal burns, and has been launched in Europe and Israel. MediWound is currently conducting a Phase 3 clinical study with NexoBrid in the U.S. for the removal of eschar in adults with deep-partial and full-thickness thermal burns.
"In addition to the U.S. government's interest in NexoBrid in preparing for burn mass casualty events, last fall the Disaster Committee of the International Society for Burn Injuries (ISBI) recommended inclusion of NexoBrid in their draft plan for mass casualty events, as they too see a role for NexoBrid in providing relief in the expected bottleneck in hospitals after such disasters. We look forward to working with various international agencies and with governments to advance the use of NexoBrid for mass casualty and disaster preparedness, as well as in military medicine," added Mr. Cohen.
About BARDA
The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies and diagnostic tools for public health medical emergencies.
About Emergency Use Authorization (EUA)
The Emergency Use Authorization (EUA) allows FDA to help strengthen the U.S. public health protections against chemical, biological, radiological, and nuclear (CBRN) threats by facilitating the availability and use of medical countermeasures needed during public health emergencies. Under the Federal Food, Drug, and Cosmetic Act, the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when there are no adequate, approved, and available alternatives.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency and from the Israeli Ministry of Health for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, clinical trials and the regulatory authorizations. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the FDA or the EMA regulatory approval process, or additional competition in the market. In particular, you should consider the risks discussed under the heading "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2014 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Contacts: Anne Marie Fields
Sharon Malka Senior Vice President
Chief Financial & Operation Officer LHA
MediWound Ltd. 212-838-3777
ir@mediwound.co.il afields@lhai.com
Any chance they'll be announcing the first spinoff on Thursday? If so, what might be the first piece to go?
I'll really celebrate if we gap up on Friday!!
They've been trying to market this for years.
Today's message tells me they're still stalling
for time.
Very very frustrating!!
Online link to Conference Call???
There may be a crazy explanation for what's happening.
Maybe, just maybe, some big player
thinks he's clearing out his position in
Marathon Petroleum!!!!
I don't know whether its a buyout or Natcore's first plant design and development contract... but the next few months should be very eventful.
On the possibility of a buyout let me point out that when Natcore research first was consolidated in Rochester we learned that Kodak's old production equipment might be suitable to produce Natcore solar panels. Nothing more has been said about this. But now Natcore headquarters have moved to Rochester. Any possibility that Kodak might see a new future with Natcore's technology?
And then there's GE. They're really big on solar. Maybe they'd have an interest.
Aluminum in place of silver... Alcoa is venturing out in lots of new directions lately.
Glass panels? How far away from Rochester is Corning Glass?
All kinds of possibilities.........
Is this the $10 Million line of credit that is being cancelled or renegotiated by Natcore? If so, we may be awaiting a buyout offer from someone and not simply a licensing agreement.
This should finally do it.
Next, our first real contract!!
Tally ho!!
What have you heard about the FN listing?
Guessing, I'd think it is most likely that the private tranche monies closed on 7/28 and 8/4 would be more than sufficient to pay for the additional research that eliminates silver.
With fingers crossed I'm thinking that this $10M will buy us a piece of our first customer's operation.
If we're announcing it now maybe we'll need it very soon.
If you're correct, I call this more research!!
By the time it's done, Natcore will have announced their next breakthrough.
Customers will then wait until the new breakthrough is refined
before they sign on.
That's how this story drags on and on and on and on!!
It all depends why they want these funds.
If they're to pay for more and more research.... Agggh!!
But if they're to buy an interest in our first customer... Hooray!!
Natcore Technology Begins Trading on OTCQB
Rochester, NY — (July 22, 2015) —Natcore Technology Inc. (TSX-V: NXT; OTCQB: NTCXF; DAX: 8NT) has been approved to trade on OTCQB, an over-the-counter marketplace organized for venture-stage or early-stage companies.
This is an upgrade from OTC Pink (the “pink sheets”), where Natcore had previously traded. To be quoted on OTC Pink, companies are not required to file with the SEC. But on June 2, Natcore announced that it had become fully reporting with the SEC, a prerequisite to being upgraded to OTCQB.
On the OTCQB, Natcore’s trading symbol will continue to be NTCXF, as it was on OTC Pink.
“The U.S. is the largest financial market in the world,” says Chuck Provini, Natcore’s president and CEO. “The OTCQB alone puts us in a marketplace where there were $63 billion in trades last year. We remain listed on the Toronto Venture Exchange (TSX-V), where there were $15 billion in trades in 2014. Combined, the two will offer Natcore investors outstanding liquidity and trade execution.”
American investors can now follow Natcore on http://www.otcmarkets.com/stock/NTCXF/quote, where share prices are quoted in U.S. dollars. On TSX-V, they are quoted in Canadian dollars.
OTC Markets Group Inc. organizes securities into marketplaces to distinguish levels of opportunity and risk: OTCQX, which it calls “The Best Marketplace with Qualified Companies”; OTCQB, positioned as “The Venture Stage Marketplace with U.S. Reporting Companies”; and OTC Pink, described as “The Open Marketplace with Variable Reporting Companies.”
Natcore was organized in August 2007. The company went public in May 2009 on the Toronto Venture Exchange (TSX-V). In June 2013, the company also became listed on the Quotation Board of the Frankfurt Stock Exchange, where its symbol is 8NT.
About Natcore Technology
Natcore Technology is focused on using its proprietary nanotechnology discoveries to enable a variety of compelling applications in the solar industry. Specifically, the company is advancing applications in laser processing, black silicon and quantum-dot solar cells to significantly lower the costs and improve the power output of solar cells. With 59 patents (24 granted and 35 pending), Natcore is on the leading edge of solar research. www.NatcoreSolar.com